Truist raises Encompass Health stock price target on strong results
Truist Securities raised its price target on Encompass Health (NYSE:EHC) to $156 from $150, citing strong Q3 results. The company reported adjusted EBITDA of $1.52B and a 32% stock return over six months. Encompass Health raised its guidance despite headwinds and is expanding capacity. The stock trades near its 52-week high of $133.75, with a financial health score of 3.35 out of 5.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise underpin Truist's target increase, indicating stronger cash flow and growth prospects.
Market read
Analyst upgrade on a health‑care provider with solid earnings could prompt short‑term buying in EHC and related peers.
What to watch
Potential headwinds from provider tax contributions and broader health‑care cost pressures.
Background
Encompass Health reported Q3 2026 earnings that beat expectations, with adjusted EPS of $1.52 versus $1.36 forecast and revenue of $1.61 B.
Ticker impact
Truist raised its price target on Encompass Health to $156 from $150 after the company posted strong Q3 results and raised guidance.
likely upward pressure as investors price in the higher target and strong earnings.
The target increase follows better‑than‑expected earnings, margins and guidance, which typically drive short‑term buying.
Market effects
Positive signal for the inpatient rehabilitation and health‑care services sector.
U.S. health‑care stocks may see modest gains.
Limited; primarily U.S. equity market impact.
Counterpoint
The target raise may already be priced in, limiting upside.
Key entities
- AnalystTruist Securities
Raised price target and maintained Buy rating.
- CompanyEncompass Health Corp
Delivered strong Q3 results and raised full‑year outlook.
